Based on a comprehensive analysis of peer-reviewed literature and our continued commitment to providing clinicians with genetic insights to help inform treatment decisions, we:
Updated certain variants of CYP3A4, HTR2A, and UGT2B15
Added medications for tardive dyskinesia
Modified results for various antipsychotics and anxiolytics/hypnotics
The report classifies over 60 mental health medications into three categories.
The GeneSight test results do not provide information on disease diagnosis, medication allergies, drug-drug interactions, or which medications will work best.
GeneSight Psychotropic upgrades are available for all previously tested patients. Upgrades may be warranted if you are considering valbenazine (Ingrezza®) or deutertrabenaznie (Austedo®) for the previously tested patient or if their results detected the UGT2B15*2 allele and/or CYP3A4*15A allele.
If you have specific questions on whether an upgrade may be warranted for a specific patient, please contact our Medical Information Team.
A new patient consent and sample may be required to upgrade.
If the patient has the most recent GeneSight report (released May 18th, 2024), no new sample is needed.
If the report is from an earlier version, a new sample will be required.
The MTHFR report has been updated to align with the design of the GeneSight Psychotropic report. Additional information has also been added to enhance clarity and better assist with report interpretation.
Since the patient’s genetic results remain unchanged, there is not currently an option to upgrade the MTHFR report. However, all future orders will reflect the updated report design.
We’re here to help! Please contact our Medical Information Team.
Call 855.891.9415
Dr. Rachael Hart Earls
PhD in Molecular Neuroscience
Medical Science Liaison Manager
Dr. Earls helps support pharmacogenomic education efforts, medical strategy, and evidence generation to advance the science of psychiatric pharmacogenomics.